Passage Bio (NASDAQ:ORIC) Now Covered by Analysts at Guggenheim

Share on StockTwits

Guggenheim began coverage on shares of Passage Bio (NASDAQ:ORIC) in a research report sent to investors on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $45.00 price target on the stock.

ORIC stock opened at $29.04 on Tuesday. Passage Bio has a twelve month low of $24.26 and a twelve month high of $34.70.

Passage Bio (NASDAQ:ORIC) last released its earnings results on Wednesday, May 20th. The company reported ($4.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($4.20). Equities analysts anticipate that Passage Bio will post -1.77 earnings per share for the current fiscal year.

In other news, Director Orbimed Advisors Llc bought 281,250 shares of the company’s stock in a transaction dated Friday, April 24th. The stock was bought at an average price of $25.68 per share, for a total transaction of $7,222,500.00.

Passage Bio Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

See Also: Are FAANG stocks a good investment?

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Derek Andersen Sells 8,284 Shares of Snap Inc  Stock
Derek Andersen Sells 8,284 Shares of Snap Inc Stock
Under Armour Inc  Short Interest Update
Under Armour Inc Short Interest Update
Passage Bio  Now Covered by Analysts at Guggenheim
Passage Bio Now Covered by Analysts at Guggenheim
Short Interest in Marriott Vacations Worldwide Corp  Decreases By 10.0%
Short Interest in Marriott Vacations Worldwide Corp Decreases By 10.0%
Progyny   Shares Down 1.9%  on Insider Selling
Progyny Shares Down 1.9% on Insider Selling
Oppenheimer Asset Management Inc. Buys New Stake in Ciena Co.
Oppenheimer Asset Management Inc. Buys New Stake in Ciena Co.


© 2006-2020 Ticker Report